Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from India, Pakistan and Bhutan in 2007–2011 by Sunil Sethi et al.
RESEARCH ARTICLE Open Access
Antimicrobial susceptibility and genetic
characteristics of Neisseria gonorrhoeae isolates
from India, Pakistan and Bhutan in 2007–2011
Sunil Sethi1, Daniel Golparian2, Manju Bala3, Dorji Dorji4, Muhammad Ibrahim2, Kausar Jabeen5
and Magnus Unemo2*
Abstract
Background: Knowledge on antimicrobial drug resistance and genetic characteristics of Neisseria gonorrhoeae
isolates circulating in India, Pakistan, and Bhutan is sorely lacking. In this paper, we describe the prevalence of
antimicrobial resistance and molecular characteristics of N. gonorrhoeae isolates from India, Pakistan, and Bhutan in
2007–2011.
Methods: Antimicrobial susceptibility and β-lactamase production were tested for 65 N. gonorrhoeae isolates from
India (n=40), Pakistan (n=18) and Bhutan (n=7) using Etest methodology (eight antimicrobials) and nitrocefin
solution, respectively. Resistance determinants, i.e. penA, mtrR, porB1b, gyrA, and parC, were sequenced. N.
gonorrhoeae multiantigen sequence typing (NG-MAST) was performed for molecular epidemiology.
Results: The highest resistance level was observed for ciprofloxacin (94%), followed by penicillin G (68%),
erythromycin (62%), tetracycline (55%), and azithromycin (7.7%). All the isolates were susceptible to ceftriaxone,
cefixime, and spectinomycin. Thirty-four (52%) of the isolates were producing β-lactamase. No penA mosaic alleles
or A501-altered alleles of penicillin-binding protein 2 were identified. Forty-nine NG-MAST STs were identified, of
which 42 STs have not been previously described worldwide.
Conclusions: Based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line
therapy for gonorrhoea in India, Pakistan, and Bhutan, whereas ciprofloxacin, penicillin G, tetracycline, erythromycin,
and azithromycin should not be. It is imperative to strengthen the laboratory infrastructure in this region, as well as
to expand the phenotypic and genetic surveillance of antimicrobial resistance, emergence of new resistance,
particularly, to extended-spectrum cephalosporins, and molecular epidemiology.
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Background
Gonorrhoea, caused by Neisseria gonorrhoeae, is the
most common bacterial sexually transmitted infection
(STI), with 106.1 million cases among adults estimated
in 2008 across the globe [1]. This incidence, according
to the World Health Organization (WHO) global esti-
mates, represented a 21% increase since 2005 [1,2]. Ac-
cordingly, gonorrhoea is associated with high morbidity
and socioeconomic consequences, remaining a major
worldwide public health problem [3-5]. During the past
60–70 years, N. gonorrhoeae has repeatedly demon-
strated its enormous ability to develop resistance in a
rapid manner to all antimicrobial drugs introduced for
first-line therapy, along with a large capacity for the
prompt spread of the emerged resistant strains globally
[3,4,6-12]. In recent decade in vitro resistance and treat-
ment failures with the currently recommended treat-
ment regimens for gonorrhoea, the extended-spectrum
cephalosporins (ESCs) cefixime and ceftriaxone, have
been verified in Japan and Europe [13-21]. The threat of
widespread resistance to ceftriaxone (the last remaining
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treatment option for single antimicrobial therapy) and
untreatable gonorrhoea is real [6,16,19,22]. In response to
this emergent situation the WHO has published its
‘Global Action Plan to Control the Spread and Impact of
Antimicrobial Resistance in Neisseria gonorrhoeae’ [5,23],
and subsequently, the European Centre for Disease Pre-
vention and Control (ECDC) and the Center for Disease
Control and Prevention (CDC) in the United States have
launched their supplementary regional response plans
[24,25].
Mutations in the penA gene encoding the penicillin-
binding protein 2 (PBP2) is the main determinant for
decreased susceptibility and resistance to ESCs. Acquisi-
tion of a penA mosaic gene or an alteration of amino
acid A501 in PBP2 result in increased minimum inhibi-
tory concentrations (MICs) of ESCs [12,26,27]. Further-
more, mutations in the promoter or coding sequence of
the repressor gene mtrR cause over-expression of the
MtrCDE efflux pump system that export the ESCs out
from the cell, and alterations of amino acid G101 and
A102 in the porin PorB1b (the penB resistance deter-
minant), which is encoded by the porB1b gene, result in
decreased influx of the ESCs. Those mechanisms further
decrease the susceptibility to ESCs as well as to other
antimicrobials such as penicillins, tetracyclines and
macrolides [11,12,28,29]. Resistance to ciprofloxacin is
caused by initial mutations in the gyrA gene (in particu-
lar in codon 91 and 95) that encode an altered subunit
GyrA of the enzyme DNA Gyrase, with subsequent
mutations in parC (encoding an altered subunit ParC of
the enzyme DNA Topoisomerase IV) to reach high-level
resistance [28,30].
A wide variety of antimicrobials, such as ESCs, but also
penicillins, fluoroquinolones, macrolides, tetracycline and
spectinomycin, may still be used for the treatment of gon-
orrhoea in India and Pakistan. Resistance to penicillin,
ciprofloxacin, and tetracycline has been reported in India,
Sri Lanka, Pakistan, and Bangladesh [31-37]. Further, ex-
ceedingly rare resistance (mainly single isolates) to spec-
tinomycin and azithromycin has been observed in India
and Bangladesh [32,36,37]. Finally, decreased susceptibility
to ESCs has been noted in India and Bangladesh, whereas
resistance to ESCs has not yet been reported from this re-
gion [31-37]. However, few isolates from this region have
been examined and, in most cases, disc diffusion methods
that do not reflect the exact MIC have been used for anti-
microbial susceptibility testing rather than quality assured,
internationally validated methods to determine the exact
MIC. Furthermore, genetic antimicrobial resistance deter-
minants, with the exception of determinants for ciproflox-
acin resistance [38], have never been studied.
Moreover, it is important to have detailed knowledge
about the gonococcal strain populations circulating in dif-
ferent communities, temporal and geographical changes
of the populations, and the emergence and transmission
patterns of individual strains for the prevention and
control of infection. Thus, a highly discriminative, object-
ive, and reproducible characterisation of N. gonorrhoeae
strains can be valuable [39]. Genotypic methods based on
DNA sequencing are internationally recommended, of
which N. gonorrhoeae multiantigen sequence typing (NG-
MAST) [40] or full- or extended-length porB gene se-
quencing are currently the best methods for fast, objective,
portable, highly discriminatory, reproducible, typeable,
and high-throughput characterisation [39]. In India and
Pakistan gonococcal epidemiology has been explored in a
few, mostly outdated studies, using traditional, low dis-
criminatory phenotypic typing methods, such as antimicro-
bial susceptibility testing, auxotyping, plasmid profiling,
and serotyping [41-45]. Only a few minor studies have used
genetic gel-based typing methods (e.g., restriction fragment
length polymorphism of the whole genomic DNA [46],
ribotyping, and Opa-typing [47]). Unfortunately, all these
methods suffer from a lack of an objective reading and in-
terpretation of results (compared to sequencing-based
methods), international standardisation, and a database for
international interlaboratory comparisons [39].
The present study aimed to investigate antimicrobial sus-
ceptibility, genetic resistance determinants focussing on
extended-spectrum cephalosporins and ciprofloxacin, and
the molecular epidemiology of N. gonorrhoeae strains that
were circulating in India, Pakistan, and Bhutan in 2007–
2011. Internationally recommended, validated, and quality
assured methods were applied for antimicrobial suscepti-
bility testing and molecular epidemiology (NG-MAST).
Methods
N. gonorrhoeae patients and isolates
All viable clinical isolates of N. gonorrhoeae collected at
the VMMC & Safdarjang Hospital, New Delhi, India
(n=40; 2007 (3), 2008 (1), 2009 (17), 2010 (19)), Aga Khan
University, Karachi, Pakistan (n=18; 2008 (1), 2009 (4),
2010 (3), 2011 (10)), and JDW/NR Hospital, Thimphu,
Bhutan (n=7; all from 2010) during 2007–2010 were
examined. The isolates were initially cultured from speci-
mens from the urethra (males, n=60) and cervix (females,
n=5) of patients presenting with symptoms and signs of
gonorrhoea, and verified as N. gonorrhoeae using growth
characteristics on selective culture agar media, Gram
staining and oxidase test. All gonococcal isolates were cul-
tured and stored (in −70°C freezer or lyophilized) as an in-
tegral part of the routine diagnostics and no personal
identification data of any patient was handled. Accord-
ingly, no ethical approval was required. The N. gonor-
rhoeae isolates were subsequently transported to the
WHO Collaborating Centre for Gonorrhoea and other
STIs, Örebro University Hospital, Örebro, Sweden, where
the isolates were recultured and verified as N. gonorrhoeae
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using growth characteristics on the selective modified
Thayer-Martin media, Gram staining, oxidase test and the
MicroTrak N. gonorrhoeae Culture Confirmation Test
(Trinity Biotech Plc, Co Wicklow, Ireland). All further
testing was performed at the WHO Collaborating Centre
for Gonorrhoea and other STIs in Sweden.
The 2008 WHO N. gonorrhoeae reference strains
[30] were used as quality controls in all antimicro-
bial susceptibility testing and genetic characterisation
(see below).
Antimicrobial susceptibility testing
MIC (mg/L) of all isolates were determined for ceftriax-
one, cefixime, penicillin G, tetracycline, erythromycin,
azithromycin, ciprofloxacin, and spectinomycin using
Etest methodology on Difco GC Medium Base (Becton,
Dickinson and Company, Sparks, MD, USA) supple-
mented with 1% BBL IsoVitaleX Enrichment (Becton,
Dickinson and Company, Sparks, MD, USA), according
to the instructions from the manufacturer (AB bioMér-
ieux, Solna, Sweden). MIC breakpoints used for deter-
mination of susceptibility, intermediate susceptibility,
and resistance (Table 1) were largely in accordance with
the European Committee on Antimicrobial Susceptibil-
ity Testing (EUCAST (www.eucast.org); clinical break-
points, v2.0). Production of β-lactamase was identified by
nitrocefin discs (Oxoid, Basingstoke, Hants, England).
Isolation of genomic DNA
Genomic DNA was isolated according to the manufac-
turer’s instructions in a robotised MagNA Pure instru-
ment (Roche, Basel, Switzerland) using the MagNA Pure
LC DNA Isolation Kit III.
Determination of genetic antimicrobial resistance
determinants
PCR amplification and sequencing of gonococcal genetic
resistance determinants focussing on ESCs and ciprofloxa-
cin, i.e. the penA, mtrR, penB, gyrA, and parC genes, were
performed as described elsewhere [30].
Molecular epidemiological characterisation
The more variable segments of porB (490 bp) and tbpB
gene (390 bp) examined in NG-MAST [40] were sequenced
as described previously [48]. NG-MASTallele numbers and




The results of the antimicrobial susceptibility of the N.
gonorrhoeae isolates (n=65) are summarised in Table 1.
Briefly, the resistance was highest to ciprofloxacin (94%),
followed by penicillin G (68%), erythromycin (62%),
tetracycline (55%), and azithromycin (7.7%). All isolates
(100%) were susceptible to ceftriaxone (MIC range:
<0.002-0.064 mg/L), cefixime (MIC range: <0.016-0.064
mg/L), and spectinomycin (MIC range: 4–16 mg/L). β-
lactamase was produced by 52% (n=34) of the isolates
(India: n=22, 55%): Pakistan: n=6, 33%); Bhutan: n=6,
86%)); all those isolates were considered resistant to
penicillin G (Table 1).
Genetic characterisation of penA alleles
No penA mosaic alleles or A501-altered alleles of PBP2
were identified (Table 2). According to the previously
described numbering of PBP2 amino acid sequences in
N. gonorrhoeae [16], PBP2 allele IX was the most
Table 1 Antimicrobial susceptibility of 65 Neisseria gonorrhoeae isolates from India (n=40), Pakistan (n=18), and











Ciprofloxacin S≤0.03/R>0.06a 0.064->32 61 (93.8) 4 (6.2) 0 (0)
Penicillin Gb S≤0.06/R>1a 0.016->32 44 (67.7) 20 (30.8) 1 (1.5)
Erythromycinc S≤0.25/R>0.5c 0.032-128 40 (61.5) 8 (12.3) 17 (26.2)
Tetracycline S≤0.5/R>1a 0.125-64 36 (55.4) 22 (33.8) 7 (10.8)
Azithromycin S≤0.25/R>0.5a 0.016-4 5 (7.7) 10 (15.4) 50 (76.9)
Spectinomycin S≤64/R>64a 4-16 0 (0) 0 (0) 65 (100)
Ceftriaxone S≤0.12/R>0.12a <0.002-0.064 0 (0) 0 (0) 65 (100)
Cefixime S≤0.12/R>0.12a <0.016-0.064 0 (0) 0 (0) 65 (100)
aBreakpoints according to The European Committee on Antimicrobial Susceptibility Testing. (EUCAST (www.eucast.org; Clinical breakpoints v2.0)).
bβ-lactamase was produced by 34 (52%) of the examined isolates, and all these isolates were considered as resistant to penicillin G independent on their MIC
values.
cBecause of the lack of EUCAST breakpoints, the EUCAST breakpoints for azithromycin were used also for erythromycin.
MIC, minimum inhibitory concentration.
Sethi et al. BMC Infectious Diseases 2013, 13:35 Page 3 of 8
http://www.biomedcentral.com/1471-2334/13/35
Table 2 Genetic resistance determinants for ceftriaxone, cefixime and ciprofloxacin in Neisseria gonorrhoeae isolates from India (n=40), Pakistan (n=18), and



















parC (alterations in D86,
S87, S88, E91 and A92)
Ceftriaxone (S, 100%) Nonea Nonea 42%/4.6%b 11% D/G (26%), G/S (20%), K/D
(18%), K/N (9.2%), N/D (6.2%),
K/G (4.6%), G/N (4.6%), N/G
(1.5%), G/G (1.5%)
ND ND
Cefixime (S, 100%) Nonea Nonea 42%/4.6%b 11% D/G (26%), G/S (20%), K/D
(18%), K/N (9.2%), N/D (6.2%),
K/G (4.6%), G/N (4.6%), N/G
(1.5%), G/G (1.5%)
ND ND
Ciprofloxacin (R, 93.8%) ND ND 44%/4.9%b 11% D/G (28%), G/S (20%), K/D
(15%), K/N (9.8%), N/D (6.6%),
K/G (4.9%), G/N (4.9%), N/G
(1.6%), G/G (1.6%)
S91F (100%), D86N (3.3%), S87N (4.9%), S87I
(1.6%), S87R (1.6%), E91G (36%),
E91K (15%), E91Q (4.9%)D95N (46%), D95G (41%),
D95A (10%), D95Y (1.6%)
Ciprofloxacin (I, 6.2%) ND ND None None K/D (75%), G/S (25%) S91F (100%) None
D95G (100%)
S, susceptible; I, intermediate susceptible; R, resistant; ND, not determined because the resistance determinants do not evidently affect this antimicrobial.
aThe identified penicillin-binding protein 2 (PBP2) alleles were IX (n=22), II (n=19), XIX (n=12), IV (n=7), Modified-XIV (n=3), XII (n=1), and XXXV (n=1). All these PBP2 alleles, with exception of PBP2 XXXV, contain an
insertion of aspartate in amino acid position 345 (D345a), which explains the high level of intermediate susceptibility and resistance to penicillin among the isolates [11,28].
bOne additional isolate (from Pakistan) displayed the recently described C-to-T transition mutation 120 bp upstream of the mtrC start codon, termed mtr120, that results in a novel consensus −10 element and


















prevalent (22 isolates), followed by II (n=19), XIX
(n=12), IV (n=7), Modified-XIV (n=3), XII (n=1), and
XXXV (n=1). Of these PBP2 alleles, all except PBP2
XXXV contain an insertion of aspartate in amino acid
position 345 (D345a), which explains the high level of
intermediate susceptibility and resistance to penicillin
among the isolates [11,28] (Table 2).
Genetic characterisation of resistance determinants that
increase the efflux or decrease the influx of antimicrobials
Of the 65 examined isolates, 27 (42%) showed mutations
in the inverted repeat region of the mtrR promoter (A-
deletion (n=24) and T-insertion (n=3)), while G45D
amino acid substitution in the DNA-binding motif of
MtrR was found in seven (11%) isolates, of which three
contained additionally an A-deletion in the mtrR pro-
moter region. Furthermore, one isolate from Pakistan
displayed the recently described C-to-T transition muta-
tion 120 bp upstream of the mtrC start codon, termed
mtr120, that results in a novel consensus −10 element
and generation of a novel promoter for mtrCDE tran-
scription. This mutation also results in an over-expression
of the MtrCDE efflux pump [29] (Table 2). Of the 15 azi-
thromycin resistant or intermediately susceptible isolates,
11 showed the A-deletion and two a T-insertion in the
mtrR promoter. Furthermore, penB alterations, causing a
decreased influx of antimicrobials [12,26,28], were found
in 60 of the 65 isolates (92%).
In the absence of penA mosaic alleles or A501-altered
PBP2 amino acid sequences, isolates containing both the
mtrR and penB resistance determinants still did not have
substantially enhanced MICs of the ESCs (ceftriaxone
MIC range: 0.002-0.064 mg/L; cefixime MIC range:
<0.016-0.064 mg/L), that is, as compared with the
remaining isolates (ceftriaxone MIC range: <0.002-0.064
mg/L; cefixime MIC range: <0.016-0.064 mg/L).
Genetic characterisation of ciprofloxacin resistance
determinants
In the present study, gyrA ciprofloxacin resistance muta-
tions were found universally: for example, S91F muta-
tions were identified in all 65 (100%) isolates. In
addition, gyrA D95G mutations were found in 45% of
the isolates, D95N in 43%, D95A in 9.2%, and D95Y in
1.5%. Concerning parC, A91G mutations were identified
in 33.8% of the isolates, followed by A91K in 13.8%,
A92Q in 4.6%, S87N in 4.6%, D86N in 3.1%, S82I in
1.5%, and S87R in 1.5% (Table 2).
Molecular epidemiological characterisation
Among the 65 isolates, 49 NG-MAST STs were identi-
fied (Additional file 1: Table S1), of which 42 were novel
STs (India: n=27; Pakistan: n=11; Bhutan: n=4). The pre-
dominant STs were ST6058 (n=5: Indian isolates),
ST6057 (n=4: Indian isolates), and ST6064 (n=3: Bhutan
isolates). The remaining STs were represented by only
one (39 STs) or two isolates (7 STs).
Discussion
This study reports the antimicrobial susceptibility/resist-
ance and molecular characteristics of N. gonorrhoeae
isolates from India, Pakistan, and Bhutan in 2007–2011.
A high prevalence of resistance was observed for cipro-
floxacin (94%), penicillin G (68%), erythromycin (62%),
and tetracycline (55%). These data are largely in accord-
ance with previous surveys in the Southeast Asian re-
gion. Accordingly, in India, penicillin resistance has
varied from 20% to 79%, tetracycline resistance from 0%
to 97%, and ciprofloxacin resistance from 11% to 100%
[34,49]. In Sri Lanka, 97% and 8.2% resistance have been
reported to penicillin and ciprofloxacin, respectively,
and in Bangladesh resistance to ciprofloxacin, penicillin,
and tetracycline was found to be 76%, 33% and 57%, re-
spectively [34]. Finally, in Pakistan 92%, 87%, and 78%
resistance to ofloxacin, penicillin G, and tetracycline, re-
spectively, has been noted [35].
Thus, in the present study none of the isolates was
susceptible to ciprofloxacin, with 94% and 6% of the iso-
lates being resistant and intermediately susceptible, re-
spectively. gyrA mutations (S91F) were found universally,
with many of the isolates containing additional mutations
in the quinolone resistance determining regions of the
gyrA and parC genes (Table 2), which confer a high level
of resistance to fluoroquinolones (e.g., ciprofloxacin)
[28,30,38]. The very high rate of fluoroquinolone resist-
ance may be an indicator of the overuse and misuse of this
class of antimicrobials in this region of the world, as
caused by over-the-counter availability, unregulated and
counterfeit medicines, self-medication or unqualified prac-
titioners who prescribe a full range of treatments [49,50].
Although fluoroquinolones are no longer recommended
for first-line treatment of gonorrhoea in most parts of the
world [4,11,51-54], most worryingly they are still being
used excessively by, in particular, private practitioners and
quacks in Southeast Asia.
Another very commonly prescribed antimicrobial in the
Southeast Asian region is azithromycin, which is fre-
quently used in syndromic management of STIs because
of the convenience of single oral dose therapy for many
infections and its efficacy against several STI pathogens,
including N. gonorrhoeae, Chlamydia trachomatis, Myco-
plasma genitalium, Haemophilus ducreyi, Klebsiella gran-
ulomatis, and Treponema pallidum [53,55]. Previously,
only some single N. gonorrhoeae isolates with resistance to
azithromycin have been reported in India and Bangladesh
[36,37]. However, in the present study only 77% of the
isolates were susceptible to azithromycin and 23% showed
resistance (7.7%) or intermediate susceptibility (15%),
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showing its unsuitability for use as an empirical first-
line therapy for gonorrhoea in this region. Furthermore,
resistance to azithromycin, including very high-level re-
sistance, has been described in many countries globally
[4,11,12,28,56-60]. Of the 15 isolates that showed resist-
ance or intermediate susceptibility to azithromycin in
the present study, 13 (87%) showed mutations in the
mtrR promoter, which enhances the expression of the
MtrCDE efflux pump, exporting azithromycin out from
the gonococcal cells and thus confers increased azithro-
mycin MICs in these isolates [11,12,28,29].
Among the isolates examined in this study, no resistance
was observed to ceftriaxone, cefixime, and spectinomycin.
Accordingly, ceftriaxone, cefixime, and spectinomycin can
be recommended as an empirical first-line therapy of gon-
orrhoea in this region, although judicious use of these anti-
microbials (particularly spectinomycin) is imperative. Some
single isolates with spectinomycin resistance and strains
with “less susceptibility” to ceftriaxone have been reported
in India and Bangladesh [32-34,37]. However, few isolates
from this region have been examined and mostly disc
diffusion methods (with lower breakpoints for “less suscep-
tibility” to ceftriaxone and resistance to spectinomycin
compared with international MIC-determining resistance
methods) for antimicrobial susceptibility testing have been
used rather than internationally validated, quality assured
MIC-determining methods. Nevertheless, our data, includ-
ing MICs of up to 0.064 mg/L for ceftriaxone and cefixime,
emphasise the importance of promptly implementing
expanded antimicrobial resistance surveillance in India,
Pakistan, and Bhutan. Corresponding to the absence of
resistance to ESCs, no penA mosaic alleles or A501-altered
PBP2 amino acid sequences were found in any of the
isolates. These alterations of the penA gene are critical for
resistance to cefixime and ceftriaxone [11-13,16,19].
Disquietingly, a majority of the gonococcal infections
(as well as other STIs) in India, Pakistan, and Bhutan
remain undiagnosed (using laboratory testing), or go
unreported, or both. STIs are also still considered a
taboo, and accordingly, people do not visit physicians
with their ailment. In other cases the patients have been
inadequately treated multiple times when they reach the
hospitals, or the samples are inadequately transported
to the laboratories, both of which diminish the likeli-
hood of recovering gonococcus in culture. Moreover,
most of the laboratories are not well equipped to provide
adequate culture and characterisation facilities. Hence,
there is a need to strengthen the existing system by pro-
viding more resources and training in this region for
enhanced surveillance and detection of gonorrhoea and
other STIs.
The N. gonorrhoeae population in India, Pakistan, and
Bhutan was found to be highly diversified, with 49 NG-
MAST STs identified among the 65 isolates examined
(Additional file 1: Table S1). The high number of unique
STs (n=39) may be a consequence of random sampling
(only viable isolates examined) over several years, sub-
optimal diagnostic procedures, incomplete epidemiological
surveillance and ineffective contact tracing, local emer-
gence of new STs, and import of strains from abroad.
Nevertheless, some minor ST clusters were identified, indi-
cating multiple sexual transmission chains. Furthermore,
of the 18 isolates from Pakistan, one isolate was assigned
ST368 that also was found in India, suggesting circulation
of a few common lineages between the two countries,
whereas 11 isolates were of new STs. One isolate from
India also belonged to ST1407, which has been shown to
be a internationally spread successful gonococcal clone
that accounts for the majority of the decreased susceptibil-
ity and resistance to ESCs and treatment failures with
cefixime worldwide [12,17-19,61,62]. This clone has also
shown its ability to develop high-level resistance to cef-
triaxone [19]. Surprisingly, the ST1407 isolate from India
did not contain the penA mosaic allele XXXIV (instead it
contained the penA allele XXXV) [16] that has been
strongly associated with ST1407 [12,17,20,61,63]. Accord-
ingly, despite showing high-level resistance to ciprofloxacin
and intermediate susceptibility to azithromycin, the Indian
ST1407 isolate displayed low MICs of ceftriaxone (0.008
mg/L) and cefixime (<0.016 mg/L). The seven isolates
from Bhutan (belonging to ST6061, ST6062, ST6063, and
ST6064) did not share STs with any of the isolates from
India or Pakistan.
Because of the small number of isolates examined in
the present study, the selection bias for these isolates
cultured during several years and the high number of
gonococcal infections remaining undiagnosed using la-
boratory testing in the included countries, the results of
the present study need to be interpreted with caution.
In future studies, additional isolates will hopefully be
available as well as epidemiological data linked to the
gonococcal isolates.
Conclusion
N. gonorrhoeae strains circulating in India, Pakistan, and
Bhutan are genetically highly diverse and exhibit a high
resistance to ciprofloxacin, penicillins, erythromycin,
and tetracycline. Furthermore, the resistance or inter-
mediate susceptibility to azithromycin was also high.
Consequently, cefixime, ceftriaxone, and spectinomycin,
which all isolates were susceptible to, are the only anti-
microbials that can be recommended for empirical first-
line therapy of gonorrhoea in this region. It is essential
to strengthen diagnostics capabilities, case reporting,
and contact tracing, as well as the surveillance of gonor-
rhoea and the antimicrobial susceptibility patterns and
new emergence of resistance to, in particular, the ESCs
(i.e. cefixime and ceftriaxone) in Southeast Asia. Finally,
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it is also imperative to inform timely and evidence-
based update treatment recommendations.
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Additional file 1: Table S1. Neisseria gonorrhoeae multiantigen
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